Globus Medical Owns the Miss — And That Is the Whole Argument
A guidance cut management blames squarely on itself, a record cash quarter, and a 2027 product slate carrying the entire thesis
GMED · Earnings Call · 2026-11-05
The headline is a cut; the substance is an admission
Globus Medical reported $763.7 million of Q3 2026 revenue, down 0.7% as reported, and trimmed full-year revenue guidance to $3.09 billion from a prior $3.18–3.22 billion range — roughly a 3% shave. Non-GAAP EPS guidance of $4.95–$5.05 was reiterated, implying 24–27% growth. The stock sits about 16% below its April 2026 peak of $96.82 and has clawed back 7% over the last 90 days, so this was not a report delivered into a collapsing tape.
Three causes were named for the shortfall: delayed product launches in U.S. Spine, lower contributions from competitive rep recruiting, and a Nevro recovery that slipped beyond prior expectations. What matters is not the list — it is who wrote it. Management wrote it about itself.
Pfeil refuses the macro alibi
Asked directly whether slower market growth, which a competitor had called out, explained the quarter, CEO Keith Pfeil declined the lifeline:
I'm really going to shy away from that because as I look at really our 3rd quarter, I think there's things that we could have done better to achieve the growth that we thought we were going to get.
That is a sharp contrast with his own framing three months earlier, when the same question drew a flat denial of any demand problem: “the spine market appears healthy. We haven't seen any drop-off of procedural demand.” — Keith Pfeil, President and Chief Executive Officer · 2026-08-06 Nothing in this quarter contradicts that — which makes the miss a share-and-execution story rather than a market story. The peer tape says the same thing: Zimmer Biomet spent its 2026-11-04 call discussing a commercial execution deficit, and Arthrex-adjacent AORT talked about set sales and surgeon training rather than end-market weakness. Orthopedics is having an execution quarter, not a demand quarter.
The self-diagnosis is specific. Competitive recruiting — the engine that produced ~10% U.S. Spine growth through 2025 and into early 2026 — is now a drag, and Pfeil was unusually blunt: “I feel we could have operated that a little bit better in 2026.” — Keith Pfeil, President and Chief Executive Officer · 2026-11-05 The missing variable was the sheer quantity of reps, not productivity per rep. Note also the third-highest keyword in the quarter's own lexicon: tough comp. When a company's own language leans on comparatives, it is usually telling you the base got harder, not that demand got softer.
Everything worth having was moved into 2027
The product slate did not disappear; it slipped. SCRYPT, the patient-specific implant and rod line; the XLift prone positioner paired with the Maxis Air 2-blade retractor; and EIQ, the next-generation pedicle fixation suite with AI planning and intraoperative rod bending. CFO Kyle Kline was explicit about the timing: “we don't expect to see any meaningful growth from script here in 2026... Those will be 2027 stories.” — Kyle Kline, Senior Vice President and Chief Financial Officer · 2026-11-05 On demand pent up behind the delay, Pfeil offered the line of the call: “I wouldn't call it a backlog. I would call it anticipation.” — Keith Pfeil, President and Chief Executive Officer · 2026-11-05
Nevro adds a new catalyst rather than a fix. HFX Elite, the first genuine product innovation since the $250 million acquisition, brings bolus therapy and expanded MRI labeling and launches in the first half of 2027. Nevro revenue fell 25.7% year over year and 9% sequentially, but EBITDA margin hit 19.9% — the business has been right-sized into profitability before it has been right-sized into growth.
Enabling technology is the cleanest illustration of the revenue-recognition tax Globus is voluntarily paying. Unit deployments rose 45% year over year and 23% sequentially, yet revenue grew only 24% to $34.9 million, because the company is converting to rental, lease, and volume-based structures. This was pre-announced in the May and August calls — “This year, to me, I view as a transition year” — Keith Pfeil, President and Chief Executive Officer · 2026-08-06 — so the Q4 softness against a record prior-year comp is a known, self-inflicted deferral rather than a new deterioration. The Enabling technology flywheel is being bought with near-term revenue.
The two things that are actually new
Buried under the guidance revision are two small tuck-ins that open genuinely new territory. Higgs Boson, closed in late August, is a surgical intelligence layer — Pfeil's framing is a closed loop that matches patient to implant and monitors outcomes post-op, with the stated ambition of moving 10-year outcomes from 70% to 95%. Synaptive's assets, acquired through a Canadian receivership bid, take Globus into cranial neurosurgery, roughly two million procedures a year and a faster-growing market than spine. Neither contributes meaningfully in 2027. They are optionality, not numbers — and management said so.
Conspicuously absent from the entire call: tariffs. Through 2025 and into 2026, tariff refunds and trade exposure were among the market's most-discussed themes across dozens of reporters; Globus barely mentions them, consistent with a largely domestic manufacturing base. The silence is a useful tell — the problems here are internal.
The cash machine nobody is paying for
Under the miss sits an unusually clean operating story. Free cash flow hit a record $225 million despite a 13% increase in capital spending, and adjusted gross margin expanded for an eighth consecutive quarter to 69.5%, with full-year guidance of 69–70% and a mid-70s target beyond. That trajectory is visible in the reported numbers: gross margin reached 69.4% in the June quarter, up 2.8 points year over year, a recovery that began when the NuVasive manufacturing insourcing started flowing through the P&L.
Cash and securities stand at $871.2 million against $629.1 million at year-end. The company bought back $279 million of stock year-to-date — just under half of free cash flow — and the board added a fresh $500 million authorization on top of $110 million remaining. Pfeil's rationale was refreshingly unsentimental: “Share repurchases have been and continue to be an integral part of our capital allocation strategy, especially when market valuations remain depressed.” — Kyle Kline, Senior Vice President and Chief Financial Officer · 2026-11-05
He has a point. At roughly 19.8x trailing earnings and 3.4x revenue, the multiple has compressed violently from the 2024 peak, when a depressed earnings base briefly pushed the P/E above 200x. The one deliberate offset to margin expansion is research spending: R&D ran at about 4.6% of revenue in the latest reported quarter, with management flagging a step-up across 2027 that will partially net against gross margin gains.
The bet in one line
Globus is asking investors to accept a 2026 that is worse than promised in exchange for a 2027 that is unusually well stocked — and to be paid for the wait in buybacks at a de-rated multiple. The Street already models roughly 6% organic growth next year; Pfeil would only say “mid to high single digits is where we'd like to be.” — Keith Pfeil, President and Chief Executive Officer · 2026-11-05 The risk is obvious and self-inflicted again: if SCRYPT case counts ramp slowly and HFX Elite slips, 2027 becomes a third consecutive tough comp story. The reward is a business generating record cash at 69.5% gross margins trading near 15x free cash flow. The miss was real; so is the cash.